drugset / Trial / NCT00148148
A Study of Caspofungin, Liposomal Amphotericin B or the Combination of Both for Patients After Stem-Cell Transplantation
Phase 2
Completed
75 enrolled
University Hospital Muenster
Gilead Sciences · collabMerck Sharp & Dohme LLC · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The study compares the safety, efficacy and pharmacokinetics of caspofungin, liposomal amphotericin B or the combination of both in the antifungal treatment of adult patients after allogeneic haematopoietic stem-cell transplantation with granulocytopenia and persistent i.g. recurrent fever under adequate antibacterial therapy.
Timeline
- Start
- 2004-05
- Primary completion
- —
- Completion
- 2007-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amphotericin B | Unknown | 3 mg/kg | Intravenous |
| Subject | Caspofungin | Other / unclassified | 50 mg | Intravenous |